Analysts Have Conflicting Sentiments on These Healthcare Companies: Xenon (XENE), Alector (ALEC) and Caris Life Sciences, Inc. (CAI)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Xenon (XENE – Research Report), Alector (ALEC – Research Report) and Caris Life Sciences, Inc. (CAI – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Xenon (XENE)
Evercore ISI analyst Cory Kasimov maintained a Buy rating on Xenon today and set a price target of $55.00. The company’s shares closed last Friday at $44.16, close to its 52-week high of $46.00.
According to TipRanks.com, Kasimov is a 5-star analyst with an average return of
Currently, the analyst consensus on Xenon is a Strong Buy with an average price target of $56.18, a 23.7% upside from current levels. In a report issued on February 23, Wolfe Research also initiated coverage with a Buy rating on the stock with a $60.00 price target.
See the top stocks recommended by analysts >>
Alector (ALEC)
Mizuho Securities analyst Graig Suvannavejh maintained a Hold rating on Alector today and set a price target of $1.50. The company’s shares closed last Friday at $2.46.
According to TipRanks.com, Suvannavejh is a 5-star analyst with an average return of
Currently, the analyst consensus on Alector is a Hold with an average price target of $2.10, implying a -16.3% downside from current levels. In a report issued on February 25, TD Cowen also maintained a Hold rating on the stock.
Caris Life Sciences, Inc. (CAI)
In a report released yesterday, Kyle Mikson CFA from Canaccord Genuity maintained a Hold rating on Caris Life Sciences, Inc., with a price target of $30.00. The company’s shares closed last Friday at $21.20, close to its 52-week low of $17.15.
According to TipRanks.com, CFA is a 1-star analyst with an average return of
Currently, the analyst consensus on Caris Life Sciences, Inc. is a Strong Buy with an average price target of $40.67, which is a 92.2% upside from current levels. In a report released today, TipRanks – DeepSeek also reiterated a Hold rating on the stock with a $20.50 price target.
